2014
Advancing pharmacovigilance through academic–legal collaboration: the case of gadolinium-based contrast agents and nephrogenic systemic fibrosis—a research on adverse drug events and reports (RADAR) report
Edwards BJ, Laumann AE, Nardone B, Miller FH, Restaino J, Raisch DW, McKoy JM, Hammel JA, Bhatt K, Bauer K, Samaras AT, Fisher MJ, Bull C, Saddleton E, Belknap SM, Thomsen HS, Kanal E, Cowper SE, Abu Alfa AK, West DP. Advancing pharmacovigilance through academic–legal collaboration: the case of gadolinium-based contrast agents and nephrogenic systemic fibrosis—a research on adverse drug events and reports (RADAR) report. British Journal Of Radiology 2014, 87: 20140307. PMID: 25230161, PMCID: PMC4170864, DOI: 10.1259/bjr.20140307.Peer-Reviewed Original ResearchConceptsGadolinium-based contrast agentsAdverse drug eventsDrug eventsMedicines AgencyGadopentetate dimeglumineDrug Administration Adverse Event Reporting SystemAdverse Event Reporting SystemDanish Medicines AgencyNephrogenic systemic fibrosisEvent Reporting SystemEuropean Medicines AgencyNSF casesHistopathological dataContrast agentsSystemic fibrosisDrug AdministrationLegal data setsUnconfounded casesGadobenate dimeglumineMean numberDimeglumineReporting systemPharmacovigilance researchSafety informationPharmacovigilance
2013
Pediatric nephrogenic systemic fibrosis is rarely reported: a RADAR report
Nardone B, Saddleton E, Laumann AE, Edwards BJ, Raisch DW, McKoy JM, Belknap SM, Bull C, Haryani A, Cowper SE, Abu-Alfa AK, Miller FH, Godinez-Puig V, Dharnidharka VR, West DP. Pediatric nephrogenic systemic fibrosis is rarely reported: a RADAR report. Pediatric Radiology 2013, 44: 173-180. PMID: 24057195, PMCID: PMC3946726, DOI: 10.1007/s00247-013-2795-x.Peer-Reviewed Original ResearchConceptsNephrogenic systemic fibrosisSystemic fibrosisGadolinium-based contrast agentsDrug Administration Adverse Event Reporting SystemAdverse Event Reporting SystemEvent Reporting SystemRenal functionPediatric casesResearch RegistryContrast agentsFibrosisDuplicate reportingU.S. FoodSystematic searchReported numberRegistryChildrenReporting systemFAERSExposureReportAgentsMethodsWeCases
2011
Nephrogenic systemic fibrosis: Clinicopathological definition and workup recommendations
Girardi M, Kay J, Elston DM, LeBoit PE, Abu-Alfa A, Cowper SE. Nephrogenic systemic fibrosis: Clinicopathological definition and workup recommendations. Journal Of The American Academy Of Dermatology 2011, 65: 1095-1106.e7. PMID: 21724294, DOI: 10.1016/j.jaad.2010.08.041.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsDiagnosis of NSFNephrogenic systemic fibrosisClinicopathological definitionNSF diagnosisWorkup recommendationsPrior clinical experienceClinicopathological presentationRenal diseaseHistopathological featuresRisk factorsStudy populationPrecise causationSystemic fibrosisClinical experienceAccurate diagnosisClinical expertiseDiagnostic standardHistopathological atlasDiagnosisGold standardMedical investigationsCompelling associationPhysiciansIndisputable linkContrast agentsNephrogenic Systemic Fibrosis and Gadolinium-Based Contrast Agents
Abu-Alfa AK. Nephrogenic Systemic Fibrosis and Gadolinium-Based Contrast Agents. Advances In Kidney Disease And Health 2011, 18: 188-198. PMID: 21531325, DOI: 10.1053/j.ackd.2011.03.001.Peer-Reviewed Original ResearchConceptsAcute kidney injuryNephrogenic systemic fibrosisGadolinium-based contrast agentsCKD stage 4Immediate hemodialysisSystemic fibrosisAdministration of GBCAsCare of patientsStage 4Needs of patientsMajority of casesKidney injuryDialysis initiationPeritoneal dialysisSignificant morbidityKidney diseaseCurrent recommendationsHigh riskContrast agentsLower riskRisk differencePatientsDrug AdministrationHemodialysisIndividualized assessment
2009
Gadolinium‐based contrast agents and nephrogenic systemic fibrosis: Why did it happen and what have we learned?
Weinreb JC, Abu‐Alfa A. Gadolinium‐based contrast agents and nephrogenic systemic fibrosis: Why did it happen and what have we learned? Journal Of Magnetic Resonance Imaging 2009, 30: 1236-1239. PMID: 19938035, DOI: 10.1002/jmri.21979.Commentaries, Editorials and LettersGadolinium‐containing magnetic resonance image contrast agent promotes fibrocyte differentiation
Vakil V, Sung JJ, Piecychna M, Crawford JR, Kuo P, Abu‐Alfa A, Cowper SE, Bucala R, Gomer RH. Gadolinium‐containing magnetic resonance image contrast agent promotes fibrocyte differentiation. Journal Of Magnetic Resonance Imaging 2009, 30: 1284-1288. PMID: 19937928, PMCID: PMC2787835, DOI: 10.1002/jmri.21800.Peer-Reviewed Original ResearchConceptsPeripheral blood mononuclear cellsNephrogenic systemic fibrosisSerum amyloid PFibrocyte differentiationDifferentiation of monocytesNSF patientsBlood mononuclear cellsHemodialysis patientsInterleukin-12Mononuclear cellsPurified monocytesFibroblast-like cellsFibrotic lesionsHealthy controlsSystemic fibrosisAmyloid PContrast agentsPatientsMonocytesDifferentiation inhibitorWiley-LissFibrocytesOmniscanDifferentiation protocolsCells
2008
Nephrogenic systemic fibrosis—Implications for nephrologists
Saab G, Abu-Alfa A. Nephrogenic systemic fibrosis—Implications for nephrologists. European Journal Of Radiology 2008, 66: 208-212. PMID: 18342470, DOI: 10.1016/j.ejrad.2008.01.028.BooksConceptsRisk of NSFChronic kidney diseaseNephrogenic systemic fibrosisContrast-induced nephropathyAdvanced chronic kidney diseaseDevelopment of NSFAdministration of gadoliniumErythropoietin therapyNephrologist's perspectiveKidney diseaseMetabolic acidosisRisk factorsMineral metabolismSystemic fibrosisNephrologist's roleHigh dosesGd-CARecent evidenceRiskContrast agentsNephropathyNephrologistsPatientsFibrosisAcidosis